Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,868,010
  • Shares Outstanding, K 607,174
  • Annual Sales, $ 2,122 M
  • Annual Income, $ 975,040 K
  • 60-Month Beta 0.98
  • Price/Sales 9.54
  • Price/Cash Flow 24.03
  • Price/Book 2.34
Trade RPRX with:

Options Overview Details

View History
  • Implied Volatility 39.91% ( +5.14%)
  • Historical Volatility 31.19%
  • IV Percentile 52%
  • IV Rank 44.09%
  • IV High 62.48% on 08/10/21
  • IV Low 22.11% on 12/22/21
  • Put/Call Vol Ratio 9.50
  • Today's Volume 21
  • Volume Avg (30-Day) 286
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 8
  • Open Int (30-Day) 1,229

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 0.79
  • Number of Estimates 3
  • High Estimate 0.80
  • Low Estimate 0.79
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +182.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.03 +2.73%
on 01/05/22
42.62 -8.33%
on 01/11/22
-0.15 (-0.38%)
since 12/21/21
3-Month
36.18 +7.99%
on 10/27/21
43.68 -10.55%
on 11/16/21
+1.57 (+4.19%)
since 10/21/21
52-Week
34.86 +12.08%
on 10/06/21
53.15 -26.49%
on 01/26/21
-11.35 (-22.51%)
since 01/21/21

Most Recent Stories

More News
Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021...

RPRX : 39.01 (-0.76%)
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into a definitive agreement to become a publicly traded...

DNAC : 9.83 (-0.10%)
RPRX : 39.01 (-0.76%)
Royalty Pharma (RPRX) Surges 5.4%: Is This an Indication of Further Gains?

Royalty Pharma (RPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

RPRX : 39.01 (-0.76%)
Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference

2021 Net cash provided by operating activities (GAAP) expected to be in the range of $2,010 to $2,030 million; 2021 Adjusted Cash Receipts (non-GAAP)...

RPRX : 39.01 (-0.76%)
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of AficamtenRoyalty...

RPRX : 39.01 (-0.76%)
CYTK : 30.22 (-1.91%)
Royalty Pharma Announces 12% Dividend Increase

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the...

RPRX : 39.01 (-0.76%)
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan...

RPRX : 39.01 (-0.76%)
Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at...

RPRX : 39.01 (-0.76%)
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and...

RPRX : 39.01 (-0.76%)
BCRX : 13.49 (-3.51%)
Pre-Market Brief: Stocks Set to Open Higher as U.S. Retail Sales Beat Expectations

Morning Markets Dec S&P 500 futures this morning are trading slightly higher. A gain of nearly +2% in Walmart in pre-market trading is supportive for the overall market after Walmart reported better-than-expected...

WMT : 141.30 (+0.06%)
RIVN : 64.34 (-1.05%)
FND : 98.33 (-2.14%)
RPRX : 39.01 (-0.76%)
TSLA : 963.00 (-3.34%)
MARA : 23.14 (-6.81%)
RIOT : 16.02 (-8.30%)
COIN : 195.99 (-11.56%)
BTBT : 4.76 (-7.21%)
ONON : 25.75 (-1.94%)
SOFI : 14.24 (-5.07%)
DNMR : 4.77 (-2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 41.14
2nd Resistance Point 40.76
1st Resistance Point 40.04
Last Price 39.01
1st Support Level 38.94
2nd Support Level 38.56
3rd Support Level 37.84

See More

52-Week High 53.15
Fibonacci 61.8% 46.16
Fibonacci 50% 44.01
Fibonacci 38.2% 41.85
Last Price 39.01
52-Week Low 34.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar